Increased amino acids levels and the risk of developing of hypertriglyceridemia in a 7-year follow-up by D. O. Mook-Kanamori et al.
ORIGINAL ARTICLE
Increased amino acids levels and the risk of developing
of hypertriglyceridemia in a 7-year follow-up
D. O. Mook-Kanamori • W. Ro¨misch-Margl • G. Kastenmu¨ller • C. Prehn •
A. K. Petersen • T. Illig • C. Gieger • R. Wang-Sattler • C. Meisinger •
A. Peters • J. Adamski • K. Suhre
Received: 20 September 2013 / Accepted: 10 December 2013 / Published online: 9 January 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Background Recently, five branched-chain and aromatic
amino acids were shown to be associated with the risk of
developing type 2 diabetes (T2D).
Aim We set out to examine whether amino acids are also
associated with the development of hypertriglyceridemia.
Materials and methods We determined the serum amino
acids concentrations of 1,125 individuals of the KORA S4
baseline study, for which follow-up data were available
also at the KORA F4 7 years later. After exclusion for
hypertriglyceridemia (defined as having a fasting triglyc-
eride level above 1.70 mmol/L) and diabetes at baseline,
755 subjects remained for analyses.
Results Increased levels of leucine, arginine, valine,
proline, phenylalanine, isoleucine and lysine were signifi-
cantly associated with an increased risk of hypertriglycer-
idemia. These associations remained significant when
restricting to those individuals who did not develop T2D in
the 7-year follow-up. The increase per standard deviation
of amino acid level was between 26 and 40 %.
Conclusions Seven amino acids were associated with an
increased risk of developing hypertriglyceridemia after
7 years. Further studies are necessary to elucidate the
complex role of these amino acids in the pathogenesis of
metabolic disorders.
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Introduction
Hypertriglyceridemia is one of the most important risk
factors for cardiovascular diseases, such as myocardial
infarction and stroke [1]. Over the past decade studies have
focused on searching for biomarkers that would allow for
early prediction of hypertriglyceridemia. Genome-wide
association studies have revealed numerous loci that are
associated with triglyceride levels [2]. However, the
overall explained proportion of the heritability by the gene
variants is low (about 10 %) and the predictive value is
limited [3].
Mass spectroscopy allows for the simultaneous mea-
surement of many metabolites from a single sample and
has proven to be a powerful and accurate tool for bio-
marker research [4–7]. A recent genome-wide association
study showed strong association between several loci of
genetic variance and metabolite levels [4]. Metabolites also
serve as intermediate traits in the analysis of gene–envi-
ronment interactions and the development of complex
diseases, such as type 2 diabetes (T2D) and cardiovascular
disorders [4]. Metabolic traits are functional readouts of
biological processes and may improve disease prediction
when they are close to a pathogenic pathway [4]. Most
interesting are longitudinal studies that associate metabolic
patterns at baseline with clinical outcomes in a follow-up
study that is ideally conducted many years later. However,
few longitudinal studies with metabolic traits measured at
baseline are available so far [7].
One successful example of a study identifying metabolic
biomarkers of longitudinal disease outcome is the Fra-
mingham Offspring Study. Wang et al. [7] found that five
branched-chain and aromatic amino acids were associated
with the risk of developing T2D in a 12-year follow-up.
These findings have been replicated in other follow-up
studies [8, 9]. Increased amino acid levels have been shown
to induce skeletal muscle insulin resistance [10]. Also,
branched-chain and aromatic amino acid levels are known
to be increased in obese individuals [11]. Branched-chain
amino acids have also been suggested to have a role in
pathophysiological processes in heart disease [12]. Thus,
there appears to be a relationship between these metabolic
biomarkers and the pathogenesis of cardio-metabolic dis-
eases. However, the precise role of these amino acids in the
development of dyslipidemia remains largely unknown.
Since hypertriglyceridemia is an important independent
cardiovascular risk factor, we ask the question of whether
amino acids are associated with hypertriglyceridemia,
independent of diabetes, and examine the relationship
between amino acids and hypertriglyceridemia in a 7-year
follow-up in a population-based study. We hypothesized
that especially baseline branched-chain and aromatic amino
acid levels would be associated with hypertriglyceridemia.
Research design and methods
Study design and population
This study was embedded in the KORA S4 study (S4) and
its 7-year follow-up KORA F4 study (F4). KORA (Coop-
erative Health Research in the Region of Augsburg) is a
research platform that has been performing longitudinal
population-based surveys and sampling and has been
described previously in detail [13, 14]. This study was
approved by the ethics committee of the Bavarian Medical
Association. Written informed consent was obtained from
all participants in accordance with institutional guidelines
and the Declaration of Helsinki Principles.
The amino acid levels of 1,614 subjects aged
55–74 years in S4 were determined. Fasting triglyceride,
amino acids levels, and information regarding T2D at both
time points were available in 1,125 subjects. Hypertri-
glyceridemia was defined as having a fasting triglyceride
level above 1.70 mmol/L [1]. T2D was defined as being
diagnosed as a person with T2D based on a self-reported
physician diagnosis and consequently validated by con-
tacting the treating physician. After exclusion of subjects
with hypertriglyceridemia and T2D at baseline, 755 sub-
jects were eligible for analyses.
Amino acid and triglyceride measurements
In both S4 and F4, fasting serum samples (at least 8 h) for
amino acids and triglycerides were collected during the
study center visit and has been described previously [14,
15]. Targeted metabolite quantification by electrospray
ionization (ESI) tandem mass spectrometry (MS/MS) was
performed using the AbsoluteIDQTM kits p180 (BIO-
CRATES Life Sciences AG, Austria) for the KORA sur-
veys S4 and resulting in the quantification of 188
metabolites. The techniques using LC–MS/MS and/or FIA-
MS/MS (FIA: flow injection analysis) have previously
been described in detail [15, 16]. Briefly, the assay prep-
aration was done by an automated robotics system (Ham-
ilton Bonaduz AG, Switzerland) on a special 96-well
sandwich plate which implemented filter containing stable
isotope-labeled internal standards. Assays used 10 lL
plasma and included phenylisothiocyanate (PITC) deri-
vatisation of amino acids, extraction with organic solvents
and several liquid handling steps. In S4, 21 amino acids (19
proteinogenic ? citrulline ? ornithine) have been quanti-
fied. The quantification of the metabolites is achieved by
reference to appropriate internal standards. The method is
proven to be in conformance with the ‘‘guidance for
industry—bioanalytical method validation’’ published by
the food and drug administration (FDA), which implies
proof of reproducibility within a given error range [17].
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Fasting triglycerides (TG) were measured with the TGL
Flex GPO-PAP assay (Dade Behring, Germany).
Covariates
Weight and height were measured to the nearest 0.1 kg and
0.1 cm, respectively. Body mass index (BMI) was calcu-
lated as (weight/height2). Age and diagnosis of T2D were
obtained through questionnaire. Self-reported physician-
diagnosed T2D state was validated by contacting the
treating physician.
Statistical analyses
First, for each of the 21 amino acids multivariate logistic
regression was performed to assess the risk of developing
hypertriglyceridemia after 7 years, adjusting for age, gen-
der, and body mass index (model 1). Subsequently, these
analyses were additionally adjusted for baseline triglycer-
ide levels (model 2). Then, model 2 was additionally
restricted to subjects without T2D for both in S4 and F4
(model 3). Finally, to account for the possible residual
confounding of pre-diabetes or insulin resistance, model 3
was additionally adjusted for hexose levels, which has been
shown by the manufacturer to contain over 90 % glucose
(model 4). Second, we examined the relationship between
the significantly associated amino acids and the risk of
developing hypertriglyceridemia further using odds ratios
per standard deviation increase of amino acid level and
quartiles. Third, we examined the predictive value of the
amino acids using the area under the curve (AUC) on a
ROC-curve. Restricting to non-diabetics, we first deter-
mined the AUC for the risk of developing hypertriglycer-
idemia using age, gender and BMI alone. Subsequently, we
examined whether adding one amino acid at a time sig-
nificantly increased the AUC. No correction for multiple
testing was applied since many of the amino acids are
highly correlated to each other. All statistical analyses were
performed in Statistical Package for Social Sciences ver-
sion 20.0 (SPSS Inc, Chicago, IL, USA).
Results
Subject characteristics are shown in Table 1. The median
follow-up time was 7 years (90 % range 6–8 years).
Table 2 shows the p values for logistic regression analyses
for the 21 amino acids on hypertriglyceridemia after 7-year
follow-up. After adjustment for gender, age and body mass
index, seven amino acids were significantly associated with
hypertriglyceridemia (leucine, arginine, valine, proline,
phenylalanine, isoleucine and lysine). These associations
remained significant after adjustment for baseline
Table 1 Subject characteristics (n = 755)
Subject characteristic Baseline 7-year follow-up
Age (years) 63 (55–72) 70 (62–80)
Gender (% male) 399 (52.8 %) 399 (52.8 %)
Weight (kg) 75.2 (56.6–97.6) 75.5 (56.1–98.5)
Height (cm) 165.0 (8.7) 164.7 (8.8)
Body mass index (kg/m2) 27.4 (21.8–35.5) 27.5 (21.5–36.0)
Triglyceride level (mmol/L) 1.10 (0.59–1.60) 1.13 (0.59–2.30)
Values represent means (standard deviations), medians (90 % range),
or number of subjects (%)
Table 2 Relation of baseline amino acid levels and the development
of hypertriglyceridemia after 7 years
Amino acid levels at
baseline
Model 1 Model 2 Model 3 Model 4
Arginine 0.009 0.012 0.009 0.017
Leucine 0.001 0.022 0.010 0.018
Valine 8.2 3 1024 0.021 0.013 0.027
Proline 0.002 0.008 0.017 0.029
Phenylalanine 0.009 0.057 0.021 0.038
Isoleucine 9.4 3 1024 0.049 0.033 0.054
Lysine 0.022 0.073 0.042 0.069
Aspartic acid 0.094 0.21 0.11 0.13
Serine 0.24 0.15 0.12 0.17
Ornithine 0.11 0.20 0.14 0.19
Glutamine 0.31 0.19 0.16 0.20
Tyrosine 0.10 0.39 0.21 0.28
Methionine 0.16 0.47 0.31 0.32
Histidine 0.41 0.67 0.41 0.50
Asparagine 0.91 0.51 0.48 0.50
Glutamic acid 0.071 0.34 0.33 0.54
Citrulline 0.58 0.55 0.71 0.54
Glycine 0.87 0.81 0.72 0.69
Threonine 0.86 0.71 0.73 0.69
Tryptophan 0.47 0.90 0.67 0.81
Alanine 0.60 0.72 0.70 0.84
n = 755 (121 cases) for model 1 ? 2; n = 686 (103 cases) for model
3
Values represent p values for logistic regression analyses for the risk
of developing hypertriglyceridemia ([1.70 mmol/L). All amino acid
levels were log-transformed
Values in bold are significant at p \ 0.05
Model 1: adjusted for gender, age and body mass index at baseline
Model 2: adjusted for gender, age, body mass index and triglyceride
levels at baseline
Model 3: adjusted for gender, age, body mass index and triglyceride
levels at baseline and restricted to non-diabetic subjects (both at
baseline and at 7 years)
Model 4: adjusted for gender, age, body mass index, triglyceride and
hexose levels at baseline and restricted to non-diabetic subjects (both
at baseline and at 7 years)
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triglyceride levels and restriction to non-diabetic subjects.
However, after additional adjustment for serum hexose,
isoleucine (p = 0.054) and lysine (p = 0.069) were no
longer statistically significant.
Table 3 gives the odds ratio for these seven amino acids
for the risk of developing hypertriglyceridemia. All seven
amino acids showed an increase in risk of hypertriglycer-
idemia. The strongest effect was found for leucine, where
the per standard deviation increase was 40 % (95 % con-
fidence interval 9–80 %). When examining the odds ratios
per quartile of amino acid level, lysine was the only amino
acid that showed a significant trend increase (p = 0.05).
The predictive value, measured by area under the curve
(AUC) of a ROC-curve, for gender, age, body mass index
and triglyceride level on the risk of hypertriglyceridemia
was 72.3 %. Though all seven significantly associated
amino acids did improve this model slightly, the
improvement was minimal and not statistically significant
(largest increase for proline was 1.7 %).
Discussion
In this population-based study, we show associations of
seven amino acids with the risk of developing hypertri-
glyceridemia after 7-year follow-up. All seven remained
significant after restriction to non-diabetic subjects (both at
baseline and follow-up) and five of them remained signif-
icant after adjustment for hexose. Several of the amino
acids found to be associated with hypertriglyceridemia
(more precisely, isoleucine, leucine, valine and phenylal-
anine), overlap with previous findings regarding the risk of
T2D [7]. Nonetheless, the predictive value of these amino
acids over conventional risk factors remains limited.
Some methodological issues should be considered.
Subjects with metabolite data were significantly older than
those without. We do not expect that this difference in age
materially influenced our results, but we cannot exclude
that the associations that we found may be limited to older
age groups. We classified hypertriglyceridemia using a cut-
off of 1.70 mmol/L, which is recommended by the
American Heart Association [1]. Using other cut-offs did
not materially change the results, making misclassification
of hypertriglyceridemia unlikely (data not shown). Finally,
Bonferroni correction for multiple testing would be overly
conservative, since many of the amino acids are highly
correlated and not independent determinants. Also, the a
priori chance of amino acids being associated with hyper-
triglyceridemia is higher, due to their known role in glu-
cose metabolism.
The relationship between amino acids, hypertriglyceri-
demia and T2D is complex. Hypertriglyceridemia together
with both normal and impaired glucose levels predicts the
development of T2D [18, 19]. Wang et al. [7] previously
described that higher levels of isoleucine, leucine, valine,
tyrosine and phenylalanine were associated with an
increased risk of T2D after a 12-year follow-up. We found
that these same amino acids (except tyrosine) were also
associated with hypertriglyceridemia. The associations
between amino acids and hypertriglyceridemia were found
in non-diabetic subjects. Firstly, a potential mediating
mechanism for these associations may be through the
branched-chain amino acid-derived acylcarnitines, C3- and
C5-acylcarnitines. Studies have shown that branched-chain
Table 3 Odds ratios for the risk of the development of hypertriglyceridemia after 7 years
Leucine Arginine Valine Proline Phenylalanine Isoleucine Lysine















p value 0.009 0.01 0.01 0.02 0.02 0.03 0.04
Amino acid as categorical variable















































p for trend 0.13 0.18 0.06 0.06 0.06 0.12 0.05
n = 686 (103 cases). Analyses restricted to non-diabetic subjects (both at baseline and at 7 years)
Values represent odds ratios (95 % confidence intervals) for the risk of developing hypertriglyceridemia ([1.70 mmol/L)
Values in bold are significant at p \ 0.05
Model is adjusted for gender, age, body mass index and triglyceride levels at baseline
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and aromatic amino acids, as well as C3- and C5-acyl-
carnitines, can affect insulin sensitivity and markers of
insulin resistance [20, 21]. In our study, C3-acylcarnitine
was also associated with hypertriglyceridemia
(p = 0.003), but C5-acylcarnitine (p = 0.16) was not
(data not shown). Acylcarnitines are modified fatty acids
(which are derived from triglycerides) that are transported
through the mitochondrial membrane for beta-oxidation
[22]. Thus, acylcarnitines also directly reflect the oxida-
tion rate of amino acids and fatty acids, which may
explain why we find associations between these amino
acids and hypertriglyceridemia in subjects without T2D.
Secondly, our finding that the associations between these
amino acids and hypertriglyceridemia persisted after
excluding patients with T2D does not mean that the
mechanisms are unrelated to insulin sensitivity (which
may be present among non-diabetic subjects). In fact, a
mechanistic relationship between amino acids and insulin
sensitivity, as suggested by the observations by Wang
et al. [7], may be mediating the observations between
these amino acids and the risk of developing T2D and
hypertriglyceridemia. However, the fact that the additional
statistical adjustment for hexose did not materially change
the associations between amino acids and hypertriglycer-
idemia, make it less likely that these associations are
mediated through an insulin-resistant state. A third
potential explanation is that these amino acids may be
markers for a more general and confounding metabolic
phenotype such as body fat mass or dietary intake. Inter-
estingly, already several decades ago a small study showed
correlations of branched-chain and aromatic amino acids
with obesity [11]. In the current study, adjustment for
body mass index markedly decreased the effect size on
hypertriglyceridemia. Nonetheless, the associations for
seven amino acids remained significant, indicating that at
least a part of the effect of amino acids on triglyceride
levels is not mediated through body mass index.
Over the past years an abundance of studies have
focused on biomarkers of metabolic diseases, such as
hypertriglyceridemia and diabetes. Genome-wide associa-
tion studies have led to the identification of several new
biological pathways, such as FADS1, but all these genes
can only explain up to 10 % of the variance in triglyceride
levels [2]. Using a hypothesis-free approach to examine
numerous metabolites by means of mass spectroscopy has
proven to be successful in biomarker discovery [7]. These
biomarkers could serve as intermediate between the genes
and the phenotype, thus giving a better prediction [4].
However, in the current study the additive value of the
amino acids was marginal over classical risk factors, such
as body mass index. Also, a recent genome-wide associa-
tion study on (amongst others) amino acids, did not reveal
any associations with genes related to obesity, T2D or
triglyceride levels, further underlining the complexity of
the pathological mechanisms in these metabolic disorders
[4].
In conclusion, this study identified seven amino acids
that are associated with an increased risk of developing
hypertriglyceridemia after 7 years. Further and longer
follow-up studies are necessary to elucidate the complex
role of these amino acids in the pathogenesis of the met-
abolic disorders.
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